| Using four definitions of highly active disease (HAD) with varying criteria, alemtuzumab improved outcomes in patients with HAD, and efficacy was maintained over 9 years in highly active relapsing-remitting multiple sclerosis. |
| Efficacy in the HAD population was generally consistent with and similar to the overall Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) population. |
| No new safety signals were seen in alemtuzumab-treated patients with HAD over 9 years. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.